The Global Adipose-derived Stem Cell Market is estimated to be worth US$ 1035.13 million in 2021 and is anticipated to grow at a CAGR of 13.05% from 2022 to 2030, according to the most recent InsightAce Analytic research. ADSCs are called multipotent cells, and they play several intercellular roles in the renewal and regeneration of other tissues and cell types in the body. This is because these cells produce and secrete various cytokines, chemokines, and growth factors that function in a paracrine manner in in-vivo tissue regeneration. It is usual to extract them using liposuction or direct excision technique from abdominal adipose (fat) tissues. For instance, Adipose-derived stem cells (ADSCs) have the potential to differentiate into musculoskeletal system cell types like tendons, ligaments, and articular cartilage. The Isolation is a success rate of 100%, and the yield from adipose tissue is 40, significantly more significant than that from bone marrow. In addition, the number of cells does not seem to decrease with age, making this type of cell appealing for extracting MSCs and progenitor cells.
Although adipose-derived stem cell therapy is often regarded as a safe operation with few potential adverse effects, difficulties can arise with any kind of medical treatment. Rising regulatory support for clinical trials of ADSCs pharmaceuticals and rising investment in the research and development of regenerative therapies are two significant factors propelling the growth of the adipose-derived stem cell market. To hasten the search for and Isolation of novel therapeutics, also there has been a rise in strategic partnerships formed between academic research institutions and pharmaceutical companies. For instance, In 2019, InGeneron Increases Its Series D Financing Amount to 43 Million Dollars in Order to Bring Regenerative Cell Therapy to Clinics.
Infection is a potential complication of adipose-derived stem cell therapy due to the possibility that disease-causing bacteria, viruses, or other pathogens will be introduced during the processing phase. Also, there are some limitations to preserving and delivering the cells, which will restrict the market growth.
The global Adipose-derived Stem Cell Market is segmented in five main segments. First is Cell type which includes Autologous and Allogeneic stem cells. Second segment is product type which comprises cell line, culture media, media, sera and reagents. The third segment is disease conditions. This segment has cancer, obesity, wounds and injuries, cardiovascular diseases, Musculoskeletal diseases and others. The fourth segment has Therapeutic and research as sub-segments which will be going to lead among all the segmentation for the forecasting period. The last segment is based on end-user industries, which are cell banks & tissue banks, Research laboratories and Academic institutes, Hospitals and Trauma centers and Other end-user industries.
Regionally North America will represent an entire market of ADSCs. Research and development funding has been increasing continuously over the last decade, which will result in early and more advancements in this therapeutic area.
Some key market players are Allocure, Inc., Celgene Corporation, Pluristem Therapeutics, Inc., Intrexon, Inc., Celleris SA, Tissue Genesis, Inc., Mesoblast Ltd., Cytori Therapeutics, Antria, Inc., ThermoFisher Scientific, American CrysoStem, Merck KGaA, and Other Prominent Players.
• Allocure, Inc.
• Celgene Corporation
• Pluristem Therapeutics, Inc.
• Intrexon, Inc.
• Celleris SA
• Tissue Genesis, Inc.
• Mesoblast Ltd.
• Cytori Therapeutics
• Antria, Inc.
• ThermoFisher Scientific,
• American CrysoStem
• Merck KGaA